Press Release Dec 22 2023
Filed with NSE · · 1 page · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a notification regarding a recent USFDA inspection at its API site in Changodar, Ahmedabad. The inspection, which took place over several days, resulted in six observations, none of which were related to data integrity. The company has four Drug Master Files under approval with the USFDA and plans to address the observations noted during the inspection. This disclosure is made in accordance with regulatory requirements for transparency to investors and the exchange.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Dec 16 2023
- Press Release Dec 15 2023
- Press Release Dec 14 2023
- Press Release Dec 11 2023
- Press Release Dec 06 2023
Later from Zydus Lifesciences
- Press Release Jan 17 2024
- Zydus Lifesciences Limited Press Release Jan 19 2024
- Press Release Jan 25 2024
- Zydus Lifesciences Limited Press Release Jan 30 2024
- Press Release Feb 08 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences